NCT00911248View on ClinicalTrials.gov

PTC299 for Treatment of Neurofibromatosis Type 2

PHASE2TerminatedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Neurofibromatosis 2

Interventions

DRUG

PTC299

PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

PTC Therapeutics

INDUSTRY

NCT00911248 - PTC299 for Treatment of Neurofibromatosis Type 2 | Biotech Hunter | Biotech Hunter